BRASILIA, Sept 15 (Reuters) - Brazil's health regulator
Anvisa on Tuesday authorized AstraZeneca PLC to test its
COVID-19 vaccine on an addition 5,000 volunteers in the country
for clinical Phase III trials, the Sao Paulo university running
the test said.
The increase, in addition to 5,000 volunteers already
recruited and being vaccinated, will help provide more solid
results on the safety and efficacy of the vaccine, the Federal
University of Sao Paulo said in a statement. It said volunteers
over the age of 18 are being sought in the states of Rio Grande
do Norte and Rio Grande do Sul, at opposite ends of Brazil.
(Reporting by Anthony Boadle, Editing by Franklin Paul)
Astrazeneca (AZN)
